Cart
sales@molnova.com
1-N-Methyl-4-mercaptohistidine disulfide
CAS No. 73491-33-5
1-N-Methyl-4-mercaptohistidine disulfide( —— )
Catalog No. M37334 CAS No. 73491-33-5
1-N-Methyl-4-mercaptohistidine disulfide is a potential Duchenne chloroplast coupling factor 1 redox regulator, an oxidized form of ochratoxin A, that inhibits light-triggered CF1 ATPase activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 1669 | Get Quote |
|
| 5MG | 1397 | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name1-N-Methyl-4-mercaptohistidine disulfide
-
NoteResearch use only, not for human use.
-
Brief Description1-N-Methyl-4-mercaptohistidine disulfide is a potential Duchenne chloroplast coupling factor 1 redox regulator, an oxidized form of ochratoxin A, that inhibits light-triggered CF1 ATPase activity.
-
Description1-N-Methyl-4-mercaptohistidine disulfide is a potential Duchenne chloroplast coupling factor 1 redox regulator, an oxidized form of ochratoxin A, that inhibits light-triggered CF1 ATPase activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number73491-33-5
-
Formula Weight400.48
-
Molecular FormulaC14H20N6O4S2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC([C@@H](C(O)=O)N)C1=C(SSC2=C(C[C@@H](C(O)=O)N)N(C)C=N2)N=CN1C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
Alpha-Solamarine
Alpha-Solamarine (Solamarine) is a glycoside alkaloid isolated from Solanum nigrum.Alpha-Solamarine is inhibitory to Globodera pallid and may be used for plant defense.
-
6,7-dimethoxy-N-(4-n...
6,7-dimethoxy-N-(4-nitrophenyl)quinazoli
-
AZD0780
AZD0780 (EX-A6975) is an oral small molecule PCSK9 inhibitor being developed by AstraZeneca as a first-in-class treatment for patients with dyslipidemia that is uncontrolled with statins alone.
